Pollution by the pharmaceutical, healthcare, and agricultural sectors is driving the development of 'superbug' strains of bacteria that have become resistant to every know
With cases of drug-resistant tuberculosis on the rise again around the world, GSK has sparked hopes of a new treatment option after reporting phase 2a data with a novel antitubercular drug
In an encouraging development for the fight against antimicrobial resistance (AMR), GSK's novel antibiotic gepotidacin has shown efficacy in two phase 3 trials, setting up regulatory filing
GSK is paying $66 million upfront to license rights to Spero Therapeutics novel antibiotic tebipenem Hbr, unswayed by the FDA's decision earlier this year not to approve the drug for adults
A Franco-German joint venture company – Aurobac Therapeutics – has been formed to try to tackle the rising threat of antimicrobial resistant (AMR) infections.
